Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy



Status:Enrolling by invitation
Healthy:No
Age Range:18 - Any
Updated:6/13/2018
Start Date:July 2016
End Date:October 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy (REWARDS-Synergy)

To compare the incidence of major adverse cardiac events among a series of patients receiving
the Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have
received the Promus Premier drug-eluting stent with durable polymer.

The primary objective of this observational, real-world single-center registry is to compare
the incidence of major adverse cardiac events among a series of patients receiving the
Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have
received the Promus Premier drug-eluting stent with durable polymer. The investigators
hypothesize that the long-term incidence (each year following implantation, up to 4 years) of
major adverse cardiovascular events, after propensity matching for stent type, will be
similar between Synergy and Xience V.

Inclusion Criteria:

1. Subject >18 years of age

2. Underwent PCI with Synergy (alone) DES

Exclusion Criteria:

1. Underwent PCI with a non-Synergy DES (or scaffold) during the same index procedure

2. Patients not taking, or unable to take, dual antiplatelet therapy (DAPT) at the time
of screening for the study (patients that discontinue DAPT after enrollment will be
included)
We found this trial at
1
site
MedStar Washington Hospital Center
Washington, District of Columbia
?
mi
from
Washington,
Click here to add this to my saved trials